

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## HEALTH TECHNOLOGY APPRAISAL PROGRAMME

### Equality impact assessment – Guidance development

### STA Burosumab for treating X-linked hypophosphataemia in adults

#### Final draft guidance

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the committee addressed these?

Stakeholders raised:

- potential discrimination based on age, which could disproportionately affect economic well-being and exacerbate socioeconomic inequalities, and that XLH has a higher symptom burden in older people.
- potential discrimination based on sex as XLH disproportionately affects women (2:1 ratio).
- that XLH disproportionately affects people living with lower socioeconomic status.

Socioeconomic status is not a protected characteristic under the Equality Act 2010. However, the committee considered it together with potential equality issues related to age and sex. As its recommendation does not restrict access to treatment for some people over others, the committee agreed that these were not equality issues.

2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups?

If so, what are the barriers to, or difficulties with, access for the specific group?
N/A

3. If the recommendations have changed after consultation, is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?
No.

4. If the recommendations have changed after consultation, are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 2 and 3, or otherwise fulfil NICE’s obligations to promote equality?
N/A.

5. Have the committee’s considerations of equality issues been described in the final draft guidance, and, if so, where?
Yes, see section 3.20.

**Approved by Associate Director (name):** .....Richard Diaz.....

**Date:** 4 June 2024